Who makes Below target dose MP-3180?

Below target dose MP-3180 is developed by MediBeacon.

What development phase is Below target dose MP-3180 in?

Below target dose MP-3180 is in Phase 1.

Last reviewed 2026-04-20 · How we verify

Below target dose MP-3180

MediBeacon · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	Below target dose MP-3180
Sponsor	MediBeacon
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Below target dose MP-3180 CI brief — competitive landscape report
Below target dose MP-3180 updates RSS · CI watch RSS
MediBeacon portfolio CI